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Abstract
Background: Genes of the Raf family encode kinases that are regulated by Ras and mediate
cellular responses to growth signals. Recently, it was shown that activating mutations of BRaf are
found with high frequency in human melanomas. The Ras family member most often mutated in
melanoma is NRas.
Methods: The constitutive activation of the Ras/Raf signaling pathway suggests an impact on the
clinical course of the tumor. To address this notion, we analyzed tumor DNA from 114 primary
cutaneous melanomas and of 86 metastatic lesions obtained from 174 patients for mutations in
BRaf (exons 15 and 11) and NRas (exons 1 and 2) by direct sequencing of PCR products and
correlated these results with the clinical course.
Results: In 57.5% of the tumors either BRaf or NRas were mutated with a higher incidence in
metastatic (66.3%) than in primary lesions (50.9%). Although the majority of BRaf mutations
affected codon 599, almost 15% of mutations at this position were different from the well-
described exchange from valine to glutamic acid. These mutations (V599R and V599K) also
displayed increased kinase and transforming activity. Surprisingly, the additional BRaf variants
D593V, G465R and G465E showed a complete loss of activity in the in vitro kinase assay; however,
cells overexpressing these mutants displayed increased Erk phosphorylation. The correlation of
mutational status and clinical course revealed that the presence of BRaf/NRas mutations in primary
tumors did not negatively impact progression free or overall survival. In contrast, however, for
metastatic lesions the presence of BRAF/NRAS mutations was associated with a significantly poorer
prognosis, i.e. a shortened survival.
Conclusion: We demonstrate a high – albeit lower than initially anticipated – frequency of
activating BRaf mutations in melanoma in the largest series of directly analyzed tumors reported to
date. Notably, the clinical course of patients harboring activating BRaf mutations in metastatic
melanoma was significantly affected by the presence of a constitutive BRaf activation in these.
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Background
There are about 133,000 new cases of melanoma world-
wide each year, of which almost 80% occur in the Cauca-
sian population of North America, Europe, Australia and
New Zealand [1]. The clinical features of melanoma are
asymmetry, a coastline border, or multiple colors, i.e.
signs reflecting the heterogeneity of the melanoma cells
within one tumor. The classification system supersedes
histopathological parameters and clinical features,
thereby superficial spreading melanoma (SSM), nodular
melanoma (NM), acral-lentiginous melanoma (ALM),
and lentigo maligna melanoma (LMM) are differentiated.
However, prognosis of primary melanoma is essentially
determined by vertical tumor thickness and the presence
or absence of ulceration [2].
While it is clear that the genetic make-up of the
melanoma-prone population is very important, only few
melanomas can be ascribed to specific genetic defects.
Loss-of-function mutations in MC1-R are associated with
red hair, fair skin and the decreased capacity to tan, i.e. a
high susceptibility to melanoma [3]. About 20% of
melanoma-prone families possess germline mutations in
the CDKN2A gene, which encodes p16INK4A, and in rare
cases mutations in the gene encoding CDK4 have been
reported. Genes identified as having a role in sporadic
melanoma include CDKN2A and PTEN, while chromo-
somal regions 1q, 6q, 7p and 11q may also be involved.
Nodular melanoma display amplification of the MYC
oncogene and inactivation of p16INK4A is associated with a
poorer prognosis [4,5]. Recently, mutations in the BRAF
gene, which is localized on chromosome 7, have been
reported in melanoma [6,7].
The Raf family of serine/threonine protein kinases con-
sists of three members: A-, B- and C-Raf which differ in
their tissue distribution [8] and which have overlapping
as well as unique regulatory functions [9,10]. Beside their
influence on processes like apoptosis and differentiation
the role of Raf proteins in proliferation control is well
established. Raf is the first element of the classical cyto-
plasmic cascade module (Raf-MEK-Erk), which transmits
growth signals from activated Ras at the plasma mem-
brane to transcription factors in the nucleus.
Although the oncogenic potential of Raf has been known
for a long time [11] only very recently the presence of Raf
mutations in human tumors was described. Activating
mutations of BRaf are found in melanomas, colorectal
cancers, ovarian tumors [6], thyroid [12,13] and lung can-
cers [14,15] and colangiocarcinomas [16]. Notably, the
highest mutational rate of BRaf with up to 68% was
described for melanoma [6,7]. The majority of mutations
are present in exon 15 within or immediately adjacent to
the so-called activation segment. The most frequently
occurring amino acid alteration is V599E, which is caused
by a T ? A exchange at nucleotide 1796 [6]. In the study of
Davies et al. this V599E mutation accounted for 92% of
the mutations found in melanoma. Additional mutations
were present in exon 11 altering the glycine residues of the
highly conserved GXGXXG motif, which is found in most
kinases but also in nucleotide binding proteins like Ras.
In the present study we aimed at confirming these obser-
vations in a larger series of patients by directly analyzing
uncultured tumor biopsies to avoid any culture artifacts
and more importantly to correlate the mutational status
with the clinical course. We therefore characterized 200
tumor samples, i.e. 114 primary and 86 metastatic
melanomas with a well documented clinical follow up for
the presence of mutations in either the BRAF or NRAS
genes. To this end, our analysis revealed that constitutive
activation of the Ras/Raf signaling pathway in melanoma
metastases is significantly associated with a poorer
prognosis.
Results
Mutations within the BRAF gene
In the study of Davies et al. [6] exon 15 mutations
accounted for 94% of BRaf mutations found in
melanoma. Therefore we analyzed first exon 15 of 200
tumor samples i.e. 114 primary and 86 metastatic
melanomas. It should be noted that the primary tumors
were selected to be already in vertical growth phase in
order to ensure that the number of subsequent clinical
events was sufficient for statistical analysis. This selection
further allowed us both to dissect the tumor from neigh-
boring normal tissue and to isolate sufficient amounts of
high quality genomic DNA. The mutation data for all200
tumor samples are summarized in table 1.
The most frequent alteration was T1796A, which leads to
an exchange of valine at position 599 to glutamic acid
(V599E) (see table 1). In addition, sequencing of B-Raf
exon 15 revealed that in 14 cases two adjoining nucle-
otides were in a heterozygous state (Figure 1). To answer
the question whether both nucleotide alterations are
localized on one allele or whether two alleles were
affected by independent single nucleotide mutations, the
PCR-products were cloned and several of the resulting
clones were sequenced. We never found clones in which
only one of the two nucleotides was exchanged, but
always found either both nucleotides being altered or
both in the wild type state (Figure 1). All these 14 muta-
tions affected BRaf at position 599: GT1795-96AA, which
leads to Valine599Lysine (V599K), GT1795-96AG, which
leads to Valine599Arginine (V599R), and TG1796-97AA
which like T1796A leads to Valine599Glutamic acid
(V599E) (Table 1). In addition, in one case we observed
an A1778T mutation, which leads to an Aspartic Acid 593Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/6
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Valine (D593V) exchange. Overall the frequency of exon
15 mutations in our cohort of patients is substantially
lower than anticipated from the data reported hitherto,
i.e. 32,5% for primary and 40,7% for metastatic tumors.
Detailed analysis revealed that the presence of exon 15
mutations was dependent on the melanoma subtype, i.e.
exon 15 mutations were present in only 2 out of 32 ALM/
LMM lesions, whereas the frequency of these mutations in
NM or SSM was 42%.
In their original report Davies et al. also described, albeit
at a lower incidence, mutations in exon 11 of the BRAF
gene. These G-loop mutations occurred predominantly in
non-melanoma tumors. Nevertheless, we amplified this
exon from the 200 tumor samples as well and sequenced
the resulting amplicons. This analysis identified 3 addi-
tional mutations, i.e. G463R, G465R and G465E, in 3
individual patients, thereby confirming that mutations in
the G-loop of BRaf occur at low frequencies in melanoma.
Constitutive activation of BRaf by the exchange of Valine 
599 to Lysine or Arginine
Almost 20% of the BRaf mutations in our patient cohort
differed from the V599E mutation. This observation
prompted us to test whether these amino acid changes
would also increase kinase and transforming activity of
BRaf. To this end, expression constructs were generated by
in vitro mutagenesis covering these mutations and these
were transiently expressed in NIH3T3 cells. Two days post
transfection all 599 variants caused a change in
Table 1: Mutations in BRaf (exon 11 and 15) and NRas (exon 1 and 2) in melanoma.
All lesions Primary tumors Metastatic lesions
Complete data 
set
200 114 86
BRaf mutations 75 37.5% 39 34.2% 36 41.9%
BRaf or NRas 
mutations
115 57.5% 58 50.9% 57 66.3%
BRaf Exon 15
wt/wt 129 64.0% 78 67.5% 51 59.3%
mut/wt (V599E) 55 27.5% 30 26.3% 28 32.5%
mut/mut (V599E) 2 1.0% 1 0.9% 1 1.2%
V599R 5 2.5% 1 0.9% 4 4.7%
V599K 6 3.0% 4 3.5% 2 2.3%
codon 599 
mutations
71 35.5% 36 31.6% 35 40.7%
% of 599 
mutations not 
V599E
15% 14% 17%
D593V 1 0.5% 1 0.9% 0 0.0%
BRaf Exon 11 (G-loop)
wt/wt 197 98.5% 112 98.2% 85 98.8%
G463R 1 0.5% 1 0.9% 0 0.0%
G465R 1 0.5% 0 0.0% 1 1.2%
G465E 1 0.5% 1 0.9% 0 0.0%
G-loop 
mutations
3 1.5% 2 1.8% 1 1.2%
NRas Exon 2 (codon 61)
wt/wt 163 81.5% 96 84.2% 67 77.9%
Q61K 17 8.5% 9 7.9% 8 9.3%
Q 6 1 H 21 . 0 %10 . 9 %11 . 2 %
Q61R 18 9.0% 8 7.0% 10 11.6%
codon 61 
mutations
37 18.5% 18 15.8% 19 22.1%
NRas Exon 1 (codons 12 and 13)
wt/wt 196 98.0% 112 98.2% 84 97.7%
G 1 2 S21 . 0 %10 . 9 %11 . 2 %
G12A 1 0.5% 1 0.9% 0 0.0%
G 1 2 V 10 . 5 %00 . 0 %11 . 2 %
codon 12 
mutations
4 2.0% 2 1.8% 2 2.3%Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/6
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morphology towards a more refractile, transformed phe-
notype. After only 3 additional days of culture it was obvi-
ous that the 599 mutants reached a 1.6 to 1,7 fold higher
cell density compared to cells expressing either wild type
BRaf or an empty vector (figure 2A).
The next step was to measure the intrinsic kinase activity
of these BRaf variants. To this end, BRaf protein was
immunoprecipated two days post transfection of NIH3T3
cells with the respective expression constructs. The protein
was then subjected to a coupled in vitro kinase assay in
which the kinase cascade is reconstituted by addition of
bacterially expressed and purified GST tagged MEK and
His tagged Erk protein. On the western blot all 599
mutants showed up as double band, consistent with auto-
phosphorylation by mutant BRaf whereas BRafwt
appeared as one band (figure 2B). Furthermore, there was
a strong increase in Erk phosphorylation by all four 599
variants (figure 2B) indicating that these mutants have an
increased ability to activate MEK. The oncogenic potential
of the exchange of valine599 to arginine or lysine was fur-
ther confirmed by the ability to transform NIH3T3 cells.
Indeed, as already observed with BRafV599E, transfection of
expression vectors coding for these mutations resulted in
the development of typical foci, which were detectable
after a two week culture of confluent cells (figure 2C).
Transfection of DNA containing the respective BRafwt
cDNA or the empty vector did not yield any foci.
Sequencing of BRaf exons 15 and 11 in our melanoma
samples had led to the identification of four mutations,
which do not affect codon 599. Analysis of the activating
potential of these mutations, however, did not yield con-
sistent data. Following transfection of NIH3T3 cells with
Mutation of two adjacent nucleotides Figure 1
Mutation of two adjacent nucleotides. Following cloning of the PCR product and sequencing of independent clones we 
always observed either wild type or double mutants.
Direct sequencing of
the PCR product
Cloning of the PCR
product
Sequencing
of clones
wild type       or     GT1795-96AA
T T T C NN T
T T T CAC T T T T CT T TJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/6
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Mutations V599R and V599K like V599E increase BRaf kinase and transforming activity Figure 2
Mutations V599R and V599K like V599E increase BRaf kinase and transforming activity. NIH3T3 cells were tran-
siently transfected with expression constructs harbouring a wild type BRaf cDNA or the indicated mutant. A) Five days post 
transfection the cells per well were counted. Shown are the mean values (±SD) of 3 wells each. B) In vitro Raf kinase assay: 
Immunoprecipitated BRaf was subjected to a kinase reaction with purified MEK and ERK proteins as series connected sub-
strates. B-Raf and Phospho-ERK were detected on a western blot. A representative experiment is shown. C) Focus assay. The 
number of transformed foci overgrowing the cell monolayer was counted 18 days post transfection. For this assay the cells 
were split 2 days post transfection from a well of a 6 well plate to a 10 cm dish. Shown are the mean values (±SD) of 6 plates 
each.
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Analysis of the BRaf mutants D593V, G463R, G465R and G465E Figure 3
Analysis of the BRaf mutants D593V, G463R, G465R and G465E. NIH3T3 cells were transiently transfected with 
expression constructs harbouring a wild type BRaf cDNA or the indicated mutant. A) Cells were lysed two days post transfec-
tion and the lysates were analysed for BRaf and Phospho-Erk on a western blot. B) Quantified Phospho Erk signals from blots 
shown in A. Given are the mean values (±SD) from two experiments. C) In vitro Raf kinase assay: Immunoprecipitated BRaf was 
subjected to a kinase reaction with purified MEK and Erk proteins as series connected substrates. B-Raf and Phospho-Erk were 
detected on a western blot. A representative experiment is shown.
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expression vectors encoding the BRaf mutants D593V,
G463R, G465R or G465E did not show any visible
changes in morphology, no higher cell densities were
reached and there was no significant increase in focus for-
mation in the transformation assay (data not shown).
Still, the phosphorylation status of Erk was increased
when the mutants D593V, G463, G465R or G465E were
expressed although this increase was somewhat weaker in
comparison toV599E (figure 3A and 3B). Surprisingly,
when these BRaf mutants were immunoprecipitated and
subjected to the in vitro kinase assay the mutants D593V,
G465R and G465E showed decreased rather than
increased kinase activity (figure 3C). Only BrafG463R did
not lose its kinase function following immunoprecipita-
tion and showed slightly higher kinase activity.
Mutations in NRas and BRaf V599 are exclusive
Previous reports suggested that BRAF V599 mutation
uncouple tumor cells from their proliferation require-
ments for RAS. Hence, coincidence of activating RAS and
BRAF mutations would not result in an additional growth
advantage for the tumor cell. Indeed, Davies et al.
reported that the presence of NRAS and BRAF mutations
were mutually exclusive in the limited series of melanoma
samples they analyzed similar to our earlier finding
regarding Ras versus C-Raf mutations in a mouse model
for carcinogen induced lung tumor formation [17,18].
The analysis of the 200 melanoma lesions for mutations
within exon 1 and 2 of the RAS gene demonstrated that in
20.5% codon 12 (2%) or codon 61 (18,5%) (see table 1)
were mutated and with only one exception mutations in
NRas and BRaf were exclusive. This one exception showed
an NRasQ61R and a BRafD593V mutation. Notably, for the
D593V mutation we could not demonstrate any trans-
forming activity (data not shown).
NRAS and BRAF mutations do not necessarily persist 
during disease progression
For 24 patients we were able to analyze the mutational
status in a longitudinal fashion, i.e. in the primary tumor
and subsequently evolving metastasis. In the majority of
cases the genotype regarding BRAF (exon 11 and 15) and
NRAS (exon 1 and 2) in the different tumor lesions was
identical. However, in seven cases the genotype showed
changes (table 2). In four cases mutations in NRAS (n = 1)
or BRAF (n = 3) could only be detected in the metastatic
lesion, but not in the primary tumor. In two cases there
was a change in the way the Ras/Raf signalling pathway
was activated, i.e. the BRafV599 mutation in the primary
tumor was replaced by an NRasQ61K  mutation in the
metastasis. In one case an NRasQ61K mutation was present
in the primary tumor, but not detectable in the metastatic
lesion. Notably, this metastatic lesion also did not har-
bour any other activating mutation in the above described
regions of either RAS or BRAF.
Constitutive activation of the Ras/Raf signaling pathway in 
metastatic melanoma correlates with the clinical course
Since the Ras/Raf signaling pathway effectuates several
hallmarks of cancer, its constitutive activation may influ-
ence the clinical course of tumors. However, the recent
detection of constitutive activation of this pathway in the
majority of benign melanocytic lesions argues against this
hypothesis in melanoma [7]. To address this notion, we
correlated the mutational status of NRAS and BRAF with
the clinical course. Multivariate analysis revealed that well
established and validated prognostic parameters for pri-
mary cutaneous melanoma, i.e. tumor thickness and the
presence or absence of ulceration, did not correlate with
either the presence of any NRas or BRaf mutation (data
not shown). However, it should be noted that we only
analyzed primary tumors, which were in the vertical
growth phase. Hence, no statement concerning pre-inva-
sive tumors in the radial growth phase can be extracted
from our study. The strategy was actually chosen in order
to allow enough events with respect to disease progression
within the clinical follow up of approximately 5 years. To
this end, the presence of BRaf/NRas mutations in the pri-
mary tumor did not negatively impact progression free
(log-rank p = 0,74) or overall survival (log-rank p = 0,28)
(figure 4A).
In contrast, however, for metastatic lesions the presence of
BRAF/NRAS mutations was associated with a significantly
poorer prognosis (log-rank test p = 0,02, t-test p =
0,0013), i.e. a shortened overall survival from the removal
of the respective metastases (Figure 4B). In this respect it
is important to note, that the majority of analyzed sam-
ples were cutaneous or soft tissue metastases and that the
distribution of locations of metastases between the groups
harboring a BRAF/NRAS mutation or not was not signifi-
cantly shifted to metastatic lesions with an impaired
prognosis.
Discussion
Genes of the Raf family encode kinases that are regulated
by Ras and mediate cellular responses to growth signals.
Recently, it was shown that activating mutations of BRaf
could be found with high frequency in melanomas. In a
panel of 200 melanoma samples in 37.5% a BRaf and
57.5% BRaf or NRas mutations were present. These fre-
quencies are low compared to those, i.e. up to and 68%
for BRaf and 90% for BRaf or NRas mutations, initially
reported [6,7]. However, this lower incidence is consistent
with other more recent publications which also describe
lower frequencies for these mutations in melanoma: (i)
Lang et al. detected only 6 cases with BRafV599E in 24 sam-
ples of metastatic melanoma lesions obtained from Scot-
tish patients [19], (ii) Gorden et al. reported a frequency
of BRafV599 mutations of 40% in a cohort of 77 metastatic
melanoma lesions [20], and (iii) only 2 out of 20 primaryJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/6
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melanoma in radial growth phase harbored either a NRas
or BRaf mutation [21]. Hence, it seems likely that with
increasing sample number the frequency of NRAS and
BRAF mutations in melanoma will level at a high albeit
lower number than initially anticipated. In addition, it
has become evident from this and other reports that in
some subtypes of cutaneous melanoma, such as ALM and
LMM, BRAF mutations appear at much lower frequency.
To this end, in our patient cohort in only 3 out of 32 ALM/
LMM BRAF was mutated.
Phosphorylation of threonine 598 and serine 601 within
the BRaf activation segment is necessary for the activation
of the kinase [22]. It was suggested that the introduction
of a negative charge by the exchange of valine to glutamic
acid at position 599 might mimic these phosphorylation
events thereby leading to increased BRaf activity [6,23].
However, as shown in the present report the introduction
of positively charged residues (lysine or arginine) at posi-
tion 599 also leads to activation. Thus, the constitutive
activation of BRaf is not necessarily due to the negative
charge but the switch from a small hydrophobic to a large
hydrophilic residue seems to be sufficient. In the inactive
Raf kinase the activation segment is hidden in a hydro-
phobic pocket. Upon phosphorylation of threonine 598
and serine 601, or upon exchange of valine to a
hydrophilic residue the activation segment may become
exposed and accessible for interaction.
We have further demonstrated that all three G-loop and
the 593 mutation seem to render BRaf more active, as the
Phospho-Erk level is raised in transfected cells. The activa-
tion by these alterations, however, is substantially weaker
than that induced by the 599 mutations, since cells exper-
imentally expressing these BRaf variants do not show the
refractile phenotype, nor do they reach higher cell densi-
ties and only a few foci overgrow the monolayer of cells.
The discrepancy that the D593V, G465R and G465E vari-
ants lead to increased Erk phosphorylation if expressed in
the cell, but not if tested in an in vitro kinase assay may be
due to the fact that these mutations lead to destabilization
of the protein conformation which is functionally rele-
vant under in vitro conditions. Another possible explana-
tion would be that these mutants need a cellular partner,
which would transmit the signal to Erk. A candidate for
such a partner would be CRaf. It should be interesting to
Table 2: Longitudinal analysis of BRaf and NRas genotypes
primary tumor Metastasis
Nr. NRas61 BRaf 599 NRas61 BRaf 599
1 w tw tw tw t
2 w tw tw tw t
3 Q 6 1 Hw tQ 6 1 Hw t
4 wt wt wt V599R
5 Q 6 1 Kw tQ 6 1 Kw t
6 w tw tw tw t
7 Q 6 1 Kw tQ 6 1 Kw t
8 w tw tw tw t
9 Q 6 1 Rw tQ 6 1 Rw t
10 wt V599E wt V599E
11 wt wt wt wt
12 wt wt wt wt
wt V599E
13 wt wt wt wt
14 Q61K wt wt wt
15 wt V599R wt V599R
16 wt V599E wt V599E
Q61K wt
17 Q61K wt Q61K wt
18 wt V599E Q61K wt
19 wt V599E wt V599E
20 wt wt Q61R wt
21 wt V599E wt V599E
22 wt wt wt wt
23 wt wt wt wt
24 wt wt wt V599K
None of the samples showed mutations in BRaf exon 11 or Nras exon 1. In two cases (12 and 16) samples of two different metastasis excised from 
one patient were analyzedJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/6
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Influence of BRaf or NRas mutation on overall survival Figure 4
Influence of BRaf or NRas mutation on overall survival. Kaplan-Meier plots for overall survival for (A) primary tumors 
and (B) metastases stratified for absence (full line) or presence of either a BRAF or a NRAS mutation (dotted line). A), i.e., as 
well as B) Overall survival was measured from removal of primary tumor time or the respective metastasis to time of death.
A
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determine the constellation of cancer genes in this subset
of melanomas in which these weakly in vivo Erk activity
mutations of BRaf have been selected.
The major finding of the present study, however, is that
the presence of BRaf mutations in a metastatic melanoma
lesion is associated with a poor prognosis, i.e. shortened
survival from either the removal of the respective metas-
tases or clinical diagnosis of stage IV disease. For primary
tumors, however, the presence of BRaf mutations did not
impact the prognosis. A notion further substantiated by
the results of multivariate analysis which revealed that for
this patient cohort mutations in the BRAF gene were not
correlated with established markers for prognosis such as
tumor thickness or ulceration.
How might this discrepancy be explained? Considering
carcinogenesis as a multistage process one can assume
that in the step from primary melanoma to metastasis the
cancer cells have to undergo additional genetic or epige-
netic alterations. Our data show that in the absence of
these alteration(s) the poor prognosis properties of acti-
vated BRaf are masked. This might happen if activated
BRaf itself would counteract the development of these
alterations. In this respect it should be noted that Dong et
al. could demonstrate that oncogenic BRAF mutations
rather correlate with progression than initiation of human
melanoma [21].
There are several lines of evidence suggesting that acti-
vated Raf proteins can suppress genetic instability. For
example, if mice with lung-specific expression of activated
C-Raf (BxB) are crossed to p53-/- mice we find only an
acceleration of the development of multiple lung tumors,
but no metastatic phenotype [24]. This observation was
surprising because p53 is well known to be necessary for
the maintenance of a stable genome and in cancer cells
loss of p53 function gives rise to clones with greater malig-
nant potential [25]. The preliminary analysis by compar-
ative genomic hybridization has indeed shown that the
genome of these C-Raf BxB/p53-/- tumors is as stable as the
genome in C-Raf BxB tumors or in normal lung tissue
(Balmain and Rapp, unpublished observation). Addition-
ally, oncogenically activated RAS or RAF have been shown
to induce growth arrest or senescence rather than unre-
stricted proliferation in normal fibroblasts via up-regula-
tion of p53, p21Cip1, or p16 [26,27]. On the other hand
the Ras/Raf/Mek/Erk pathway is also clearly involved in
the oncogenic process. Raf Kinase Inhibitor Protein
(RKIP) was identified as a metastasis suppressor in pros-
tate cancer [28] placing Raf in a pro-metastatic pathway.
Moreover, high ratios of Erk/p38 signaling determine the
human head and neck carcinoma cell line (Hep3) towards
tumor growth and metastasis whereas low Erk/p38 ratios
are associated with dormancy [29,30]. The sequential
increase in the level of activated Smad2 and HRas has
been shown to drive the progression from a differentiated
squamous carcinoma to an invasive spindle cell carci-
noma [31]. The higher incidence of NRas or BRaf muta-
tions in metastasic (66.3%) than in primary melanoma
(50.9%) in this study together with the observation that
BRAF mutations are more frequent in advanced than in
early primary melanoma suggests that activation of this
pathway favors the metastatic process [21].
Therefore, activated BRaf may have two-edged features
during oncogenesis, i.e. good prognosis properties by sta-
bilizing the genome and poor prognosis properties by
contributing to several other hallmarks of cancer [23].
This is reminiscent of transforming growth factor β, which
has been implicated in both tumor suppression and pro-
gression [32]. However at the metastatic stage of the dis-
ease when the full set of genetic alterations might have
taken place the good prognosis properties become irrele-
vant and the bad prognosis properties become dominant.
A report by Kumar et al. describing the mutational status
of 38 metastatic melanomas further demonstrate the com-
plexity of the clinical consequences of constitutive BRaf
activation [33]. In their patient cohort the presence of
BRAF mutations was associated with a favorable response
to therapy, i.e. a longer progression free survival as com-
pared to cases without mutation. In our patient cohort we
did not analyze for any correlation of mutational status
and response to therapy due to the fact that the number of
objective responses induced by our therapeutic measures
(12%) was substantially lower than that observed by
Kumar et al. (55%). Hence, the number of patients eligi-
ble for this analysis was too low [34].
Is activation of the MAP kinase pathway a necessary event
for the development of melanoma? Constitutive activa-
tion of Erk is a general feature in melanoma [35] which
was attributed to the constitutive activity of BRaf and
NRas. However, in 43% of the cases we did not detect any
BRaf or NRas alterations. This is in agreement with other
studies, although the reported gap was smaller [6,7]. A
candidate to fill this gap is the lipid and protein phos-
phatase PTEN. This tumor suppressor can negatively regu-
late the MAP kinase pathway [36]. Like for BRaf/NRas a
reciprocal mutational status has been reported for NRas
and PTEN in human melanoma cell lines [37]. It will be
interesting to see whether also PTEN alterations and BRaf/
NRas mutations in melanoma are exclusive. Furthermore,
autocrine secretion of growth factors may also contribute
to increased Erk activity in melanoma cells [35]. Our
observation that NRAS and BRAF mutation are not neces-
sarily concordant in the primary tumor and the subse-
quently evolving metastases does not only illustrate the
plasticity of tumor cells, but also that different oncogenic
mechanisms resulting in activation of Erk may be engagedJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/6
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in one individual patient. In a recent report of Schmidt-
Kittler et al. it was described that genomic aberrations in
tumor cells disseminated in the bone marrow generally
do not resemble the aberrations in the primary tumor
from which they arose [38]. Hence, tumor cells seem to
disseminate very early and evolve to metastatic disease
largely independent from the primary tumor.
Conclusions
In conclusion, we demonstrate a high frequency of acti-
vating BRaf mutations, which are not restricted to the
V599E variant, in cutaneous melanoma with an increased
incidence in metastatic lesions. Strikingly, the constitutive
activation of the Ras/Raf signaling pathway was associated
with an impaired prognosis if present in metastatic but
not in primary melanoma. This indicates the intricacy of
the outcome of a constitutive activation of this signaling
pathway in the oncogenesis of melanoma.
Material and methods
Tumor material
Paraffin embedded tumor samples from 114 primary and
86 metastatic melanomas were obtained by surgical exci-
sion. All tumors have undergone routine histology for
diagnosis. The three immediately following slides from
the blocks were used for DNA extraction and the forth
slide was used to confirm the presence of the lesion. Prior
to DNA extraction adjacent normal tissue was macroscop-
ically dissected. Informed consent was obtained from all
patients prior to any of these measures.
Polymerase chain reaction
Genomic DNA was isolated from paraffin embedded
tumor samples using a DNA Isolation Kit (Qiagen).
Applying conventional PCR for BRaf exon 15 on these
templates we had frequent drop outs not yielding the
desired product. We therefore switched to nested PCR
protocols with an initial PCR reaction (22 cycles, total vol-
ume of 30 µl) followed by a second PCR reaction (35
cycles, total volume of 55 µl) containing 1 µl of the first
reaction as template. Primers and conditions for the dif-
ferent amplicons were as follows:
BRAF exon 15
First PCR reaction: 2 min at 95°C, 22 cycles (25 sec at
95°C, 25 sec at 55°C, 30 sec at 72°C) and 5 min at 72°C;
Primers: cataatgcttgctctgatagg/ggccaaaaatttaatcagtgga
Second PCR reaction: 2 min at 95°C, 35 cycles (20 sec at
95°C, 20 sec at 55°C, 30 sec at 72°C) and 5 min at 72°C;
Primers: cataatgcttgctctgatagg/tagcctcaattcttaccatc
BRAF exon 11
First PCR reaction: 2 min at 95°C, 22 cycles (30 sec at
95°C, 30 sec at 58°C, 30 sec at 72°C) and 5 min at 72°C;
Primers: gtcccgactgctgtgaa/gtttggcttgacttgacttttt
Second PCR reaction: 2 min at 95°C, 35 cycles (30 sec at
95°C, 30 sec at 58°C, 30 sec at 72°C) and 5 min at 72°C;
Primers: gtcccgactgctgtgaac/acgggactcgagtgatgatt
NRAS exon 1
First PCR reaction: 2 min at 95°C, 22 cycles (30 sec at
95°C, 30 sec at 58°C, 30 sec at 72°C) and 5 min at 72°C;
Primers: ttatccggtgtttttgcgttctc/gctaccactgggcctcacctcta
Second PCR reaction: 2 min at 95°C, 35 cycles (30 sec at
95°C, 30 sec at 58°C, 30 sec at 72°C) and 5 min at 72°C;
Primers: agtactgtagatgtggctcgc/actgggcctcacctctatg
NRAS exon 2
First PCR reaction: 2 min at 95°C, 22 cycles (30 sec at
95°C, 30 sec at 60°C, 30 sec at 72°C) and 5 min at 72°C;
Primers: cccccttaccctccacacc/gaggttaatatccgcaaatgactt
Second PCR reaction: 2 min at 95°C, 35 cycles (30 sec at
95°C, 30 sec at 53°C, 30 sec at 72°C) and 5 min at 72°C;
Primers: gattcttacagaaaacaagtg/atgacttgctattattgatgg
Sequencing
Samples were sequenced using BigDye™ Terminator Cycle
Sequencing Ready Reaction Kit (Applied Biosystems)
according to the manufacturer's manual, and analyzed on
an ABI PRISM 3100 Avant Genetic Analyzer.
Plasmid construction
For transfection into NIH3T3 cells the plasmid pCMV5-
BRaf containing a full length human BRaf cDNA was used.
The different mutations were introduced by PCR with Pfu
Polymerase (Stratagene) using mutation specific primers.
Following restriction digestion with Dpn I the PCR prod-
uct was transformed into competent DH5α E-coli cells. All
clones were verified by sequencing.
Cell culture
NIH 3T3 cells were grown under standard conditions
(37°C, 5% CO2) in DMEM (Life Technologies, Inc.) sup-
plemented with 10% heat-inactivated fetal bovine serum
(Hyclone), 168 mM L-Glutamin (Life Technologies, Inc.)
and 100 units/ml streptomycin and penicillin (Life Tech-
nologies, Inc.).
Focus assay
2 × 105 NIH 3T3 cells per well were seeded in 6 well cul-
ture plates 1 day prior to transfection. Transfections were
carried out using the Lipofectamine method (Life Tech-
nologies, Inc.) according to the manufacturers manual. 2Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/6
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days post transfection cells were split into 10 cm culture
plates. Focus formation was scored 14 – 18 days later.
In vitro kinase assay
The in vitro kinase assay procedure was similar to that
described by Weber et al. [39]. Transfected NIH3T3 cells
were harvested 2 days post transfection and washed twice
with PBS. From now on all steps were carried out on ice or
at 4°C. Cells were lysed in 1 ml NP40-buffer (25 mM Tris,
150 mM NaCl, 10 mM Na4P2O7, 25 mM β-glycerophos-
phate, 25 mM NaF, 10% glycerine, 0.75% NP-40, 20 µg/
ml Leupeptin, 20 µg/ml Aprotenin, 1 mM Benzamidine, 1
mM PMSF). For the purpose of preclearing the lysate was
incubated with 15 µl protein agarose A (Amersham) for
30 min. Following centrifugation the supernatant was
incubated for 2 hours with 30 µl protein agarose A beads
and 5 µl of a polyclonal α-BRaf antiserum. The beads car-
rying the immunoprecipitated BRaf protein were then
washed twice with NP-40 buffer and once with kinase
buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 25 mM β-
glycerophosphate, 10 mM MgCl2, 1 mM DTT). The kinase
reaction was carried out for 25 minutes in a shaker at
26°C in 60 µl kinase buffer containing 15 µM vanadate,
170 µM ATP and the bacterially expressed purified pro-
teins GST-MEK (3 µg) [40] and His-Erk-2 (400 ng) [41].
After adding 4x Laemmli buffer the samples were boiled
and the proteins were separated on a 9% SDS-Polyacryla-
midgel. Following blotting Phospho-Erk and BRaf were
detected using the monoclonal antibody α-Phospho-p44/
42 MAP kinase (Thr202/Tyr204) (Cell Signaling) and the
monoclonal α-BRaf antibody S12 [42] respectively.
Statistics
Time to progression, i.e. progression free survival, was
measured from the day of removal of the tumor lesion to
the first onset of tumor progression. Overall survival was
measured either from the first day of removal of the
respective tumor lesion or diagnosis of stage IV disease to
the last documented staging examination, i.e. the date last
seen. The Kaplan-Meier technique was used to calculate
survival data. The log-rank test was used to analyse sur-
vival differences among subgroups of patients. The sur-
vival analysis was performed in June 2003.
Bivariate analysis of the relationships between prognostic
factors and NRAS  and  BRAF  genotypes were assessed
according to the U-test following Mann and Whitney or
the student's t-test, depending on the nature and distribu-
tion of the data. Independent prognostic factors and
NRAS and BRAF genotypes should be identified in multi-
variate analysis using configuration-frequency-method. A
p-value of <0.05 was considered to be significant. All cal-
culations were performed using MEDAS statistical soft-
ware (Grund EDV-Systeme, Margetshöchheim,
Germany).
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